Apimeds Pharmaceuticals US, Inc. (APUS) stock
APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.95−0.09 (-4.41%)
Close on Nov 17, 2026Market cap $2.94MP/E –Yield –
Apimeds Pharmaceuticals US operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Apimeds Pharmaceuticals US's operating cash flow for the twelve months ending Jun 30, 2026 was -$13.28M. For fiscal 2025 it was -$8.93M.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$8.93M | – |
| FY2024 | Dec 31, 2024 | -$733.53K | – |
| FY2023 | Dec 31, 2023 | -$627.79K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.67M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.07M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.82M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.36M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.31K | – |
| Q4 FY2024 | Dec 31, 2024 | -$99.62K | – |
| Q3 FY2024 | Sep 30, 2024 | -$186.76K | – |
| Q2 FY2024 | Jun 30, 2024 | -$184.06K | – |
| Q1 FY2024 | Mar 31, 2024 | -$263.10K | – |
See a number that looks wrong?